EUVIMEDScopri EUVIMED
MetaanalyseSystematische ÜbersichtUmbrella ReviewOpen access · CC BY-NC-ND 4.0

Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis

Diabetes, antidiabetische Medikamente und Demenzrisiko: systematische Umbrella-Übersicht und Metaanalyse

Alvin Kuate Defo, Veselko Bakula, Alessandro Pisaturo iD, Christopher Labos, Simon S Wing, Stella S Daskalopoulou iD

Diabetes, Obesity and Metabolism · 2024-02 · 26 (2) · 441-462

DOI: 10.1111/dom.15331 ↗

Auf einen Blick

Die Umbrella-Übersicht und Metaanalyse fand für mehrere Antidiabetika ein geringeres Demenzrisiko. Für andere Wirkstoffe zeigte sich kein signifikanter Effekt oder ein erhöhtes Risiko.

Fragestellung

Welche Beziehung besteht zwischen Diabetes, antidiabetischen Therapien und dem Demenzrisiko?

Methode

Systematische Umbrella-Übersicht und Metaanalyse; Suche in MEDLINE/PubMed, Embase, PsycINFO, CINAHL und Cochrane Library bis 2. Juli 2023; AMSTAR und Newcastle-Ottawa Scale.

Ergebnisse

Eingeschlossen wurden 100 Reviews und 27 Kohorten-/Fall-Kontroll-Studien (N = 3 046 661). Metformin, Thiazolidinedione, Pioglitazon, GLP1RAs und SGLT2is waren mit geringerem Demenzrisiko verbunden; Meglitinide und Sulphonylharnstoffe mit höherem Risiko.

Einschränkungen

Die Metformin-Wirkung war nur in den USA sowie in westlichen, nicht östlichen Populationen signifikant.

Schlussfolgerung der Autor:innen

Metformin, Thiazolidinedione, Pioglitazon, GLP1RAs und SGLT2is waren mit reduziertem Demenzrisiko assoziiert. Weitere Längsschnittstudien sollen den relativen Nutzen in verschiedenen Populationen klären.

Kernaussagen

  • 100 Reviews und 27 Beobachtungsstudien mit N = 3 046 661
  • Metformin, Thiazolidinedione, Pioglitazon, GLP1RAs und SGLT2is: geringeres Demenzrisiko
  • Meglitinide und Sulphonylharnstoffe: erhöhtes Demenzrisiko

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Metaanalyse in Diabetes, Obesity and Metabolism, published online on 2023-10-23. Written by Alvin Kuate Defo and 5 co-authors. Institution: Vascular Health Unit, Research Institute of the McGill University Health Centre, Department of Medicine, Faculty of Medicine, McGill University, Mont…. Major MEDLINE topics: Dementia, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Metformin. Cited 78 times so far (Crossref); 145 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

Auf einen BlickAbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Aims

The objective of this umbrella review and meta‐analysis was to evaluate the effect of diabetes on risk of dementia, as well as the mitigating effect of antidiabetic treatments. Materials and Methods We conducted a systematic umbrella review on diabetes and its treatment, and a meta‐analysis focusing on treatment. We searched MEDLINE/PubMed, Embase, PsycINFO, CINAHL and the Cochrane Library for systematic reviews and meta‐analyses assessing the risk of cognitive decline/dementia in individuals with diabetes until 2 July 2023. We conducted random‐effects meta‐analyses to obtain risk ratios and 95% confidence intervals estimating the association of metformin, thiazolidinediones, pioglitazone, dipeptidyl peptidase‐4 inhibitors, α‐glucosidase inhibitors, meglitinides, insulin, sulphonylureas, glucagon‐like peptide‐1 receptor agonists (GLP1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) with risk of dementia from cohort/case‐control studies. The subgroups analysed included country and world region. Risk of bias was assessed with the AMSTAR tool and Newcastle‐Ottawa Scale.

Results

We included 100 reviews and 27 cohort/case‐control studies (N = 3 046 661). Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with significant reduction in risk of dementia. When studies examining metformin were divided by country, the only significant effect was for the United States. Moreover, the effect of metformin was significant in Western but not Eastern populations. No significant effect was observed for dipeptidyl peptidase‐4 inhibitors, α‐glucosidase inhibitors, or insulin, while meglitinides and sulphonylureas were associated with increased risk.

Conclusions

Metformin, thiazolidinediones, pioglitazone, GLP1RAs and SGLT2is were associated with reduced risk of dementia. More longitudinal studies aimed at determining their relative benefit in different populations should be conducted.

Subjects

MeSH terms (MEDLINE)

DementiaDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsMetforminSodium-Glucose Transporter 2 InhibitorsThiazolidinedionesHumansDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlycoside Hydrolase InhibitorsHypoglycemic AgentsInsulinPioglitazoneSulfonylurea CompoundsSystematic Reviews as Topic

Author keywords

Alzheimer's dementiadiabetesglucagon-like peptide-1 receptor agonistsmetforminpioglitazonesodium-glucose cotransporter-2 inhibitorsthiazolidinedionesvascular dementia

Substances

Dipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesGlycoside Hydrolase InhibitorsHypoglycemic AgentsInsulinMetforminPioglitazoneSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsThiazolidinediones

Authors and institutions

  • Vascular Health Unit, Research Institute of the McGill University Health Centre, Department of Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
  • Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada.
  • Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
  • Division of Endocrinology & Metabolism, Department of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
  • Division of Internal Medicine, Department of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.

ORCID profiles: Alessandro Pisaturo, Stella S Daskalopoulou

Cite

APA

Kuate Defo, A., Bakula, V., Pisaturo, A., Labos, C., Wing, S. S., & Daskalopoulou, S. S. (2024). Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis. Diabetes, Obesity and Metabolism, 26(2), 441-462. https://doi.org/10.1111/dom.15331

Vancouver

Kuate Defo A, Bakula V, Pisaturo A, Labos C, Wing SS, Daskalopoulou SS. Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis. Diabetes, Obesity and Metabolism. 2024;26(2):441-462. doi:10.1111/dom.15331

BibTeX
@article{KuateDefo2024,
  author = {Kuate Defo, Alvin and Bakula, Veselko and Pisaturo, Alessandro and Labos, Christopher and Wing, Simon S and Daskalopoulou, Stella S},
  title = {Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {2},
  pages = {441--462},
  doi = {10.1111/dom.15331}
}
Start for free →